Table 2.
Estimated relative prevalence reduction (percentage decrease of schistosomiasis prevalence) by species and country, comparing 2011–14 and 2015–19 with 2000–10 across sub-Saharan Africa
|
Relative prevalence reduction (2011–14) |
Relative prevalence reduction (2015–19) |
|||||
|---|---|---|---|---|---|---|
| Schistosomiasis | S haematobium | S mansoni | Schistosomiasis | S haematobium | S mansoni | |
| Angola | 39·2% | 43·2% | 21·9% | 58·2% | 61·7% | 53·6% |
| Benin | 42·8% | 44·9% | 29·8% | 65·4% | 65·6% | 69·7% |
| Botswana | 41·5% | 47·8% | 16·5% | 59·1% | 63·7% | 44·6% |
| Burkina Faso | 67·2% | 69·5% | 50·1% | 77·9% | 78·5% | 70·7% |
| Burundi | 43·7% | 67·4% | 34·0% | 69·7% | 80·1% | 64·0% |
| Cameroon | 41·1% | 53·3% | 19·9% | 68·1% | 73·1% | 60·8% |
| Central African Republic | 24·6% | 43·6% | 14·0% | 36·4% | 56·7% | 23·7% |
| Chad | 34·2% | 37·6% | 14·8% | 50·9% | 52·6% | 47·1% |
| Congo | 27·3% | 46·5% | 6·9% | 57·4% | 67·8% | 48·8% |
| Côte d'Ivoire | 36·4% | 54·6% | 17·8% | 54·9% | 67·0% | 44·4% |
| Democratic Republic of the Congo | 50·1% | 53·0% | 24·2% | 71·6% | 73·3% | 59·2% |
| Djibouti | 54·0% | 60·5% | 37·2% | 66·0% | 68·5% | 45·6% |
| Equatorial Guinea | 44·6% | 67·2% | 21·8% | 60·7% | 74·5% | 48·3% |
| Eritrea | 19·9% | 54·8% | 2·7% | 68·1% | 78·4% | 61·1% |
| Eswatini | 44·1% | 63·5% | 24·5% | 66·5% | 78·3% | 54·7% |
| Ethiopia | 32·7% | 53·0% | 9·9% | 59·7% | 69·4% | 49·3% |
| Gabon | 34·1% | 54·2% | 8·7% | 55·3% | 69·0% | 35·4% |
| Gambia | 51·0% | 52·5% | 9·5% | 71·6% | 72·0% | 65·4% |
| Ghana | 46·7% | 54·0% | 21·9% | 64·6% | 68·0% | 57·5% |
| Guinea | 15·2% | 43·8% | 7·0% | 29·0% | 58·6% | 20·4% |
| Guinea-Bissau | 45·0% | 55·3% | 33·0% | 64·3% | 71·6% | 52·9% |
| Kenya | 39·2% | 51·0% | 18·2% | 61·7% | 67·4% | 55·3% |
| Lesotho | 49·2% | 61·0% | 8·5% | 67·9% | 69·7% | 61·1% |
| Liberia | 30·1% | 51·6% | 19·3% | 43·1% | 58·2% | 38·8% |
| Madagascar* | .. | .. | .. | .. | .. | .. |
| Malawi | 45·7% | 51·2% | 28·7% | 69·4% | 70·9% | 69·8% |
| Mali | 42·9% | 46·6% | 35·4% | 56·3% | 59·3% | 55·6% |
| Mauritania | 41·6% | 44·4% | 25·0% | 56·9% | 58·7% | 48·9% |
| Mozambique | 31·8% | 40·4% | 17·3% | 47·5% | 53·0% | 43·6% |
| Namibia | 38·8% | 49·4% | 8·8% | 59·4% | 64·4% | 43·7% |
| Niger | 57·5% | 58·7% | 42·7% | 70·5% | 71·3% | 63·9% |
| Nigeria | 44·9% | 48·6% | 21·1% | 67·1% | 68·7% | 59·9% |
| Rwanda | 28·2% | 60·3% | 20·5% | 61·9% | 78·6% | 57·8% |
| Senegal | 47·5% | 52·8% | 30·9% | 64·5% | 67·7% | 55·1% |
| Sierra Leone | 44·2% | 69·2% | 37·8% | 51·3% | 79·4% | 42·5% |
| Somalia | 39·6% | 45·3% | 14·1% | 55·9% | 59·8% | 49·1% |
| South Africa | 37·3% | 46·8% | 6·8% | 55·5% | 60·3% | 40·7% |
| South Sudan | 22·3% | 48·8% | −1·6% | 46·3% | 64·3% | 32·4% |
| Sudan | 27·9% | 45·1% | 10·3% | 48·7% | 62·2% | 38·2% |
| Tanzania | 31·9% | 46·2% | 6·7% | 51·6% | 59·8% | 37·8% |
| Togo | 68·4% | 69·7% | 65·0% | 73·6% | 74·7% | 69·9% |
| Uganda | 24·9% | 53·3% | 8·9% | 62·0% | 71·5% | 55·9% |
| Zambia | 31·8% | 45·9% | 15·5% | 56·3% | 63·8% | 53·9% |
| Zimbabwe | 47·0% | 57·9% | 22·8% | 72·0% | 75·8% | 65·1% |
| Total (95% Bayesian credible interval) | 39·4% (34·3–43·6) | 51·2% (46·9–56·4) | 19·5% (9·2–27·3) | 60·5% (55·7–64·6) | 67·9% (64·6–71·1) | 53·6% (45·2–58·3) |
Relative prevalence reduction was calculated as the prevalence in 2000–10 minus the prevalence in 2011–14 or 2015–19 divided by the prevalence in 2000–10. For example, the 39·2% relative prevalence reduction of schistosomiasis in Angola during the 2011–14 period suggests that in Angola the schistosomiasis prevalence during 2011–14 decreased by 39·2% compared with the baseline prevalence during 2000–10.
*
Madagascar only had data available for 2015–19, therefore reduction prevalences could not be calculated.